<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853071</url>
  </required_header>
  <id_info>
    <org_study_id>P/2015/269</org_study_id>
    <nct_id>NCT02853071</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Estracyt® in Metastatic Breast Cancer</brief_title>
  <acronym>BEST</acronym>
  <official_title>Efficacy and Safety of Estracyt® in Metastatic Breast Cancer Hormonal Estrogen Receptor (HER 2) Negative, Hormone Receptor (HR) Positive.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates efficacy, safety and quality of life in patients affected by metastatic
      breast cancer RH+/ HER2- and treated by estramustine phosphate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients affected by metastatic breast cancer RH+/HER2-, the conventional treatment is
      hormonotherapy. But, when patients don't react no recommendations exist.

      Estramustine phosphate is currently prescribed for prostate cancer. The estramustine
      phosphate is an active anti-tumoral agent by oral route, associating a nitrogenous mustard
      with the estradiol, it settles on membrane receptor and the cytotoxic component acts
      essentially by dismantling microtubules inhibiting the mitosis.

      Estramustine could be a therapeutic option when currently therapy are exhausted for patients
      reactive to hormonotherapy previous lines or chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of the alive patients without progress of the disease</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>18 months</time_frame>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Estramustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>560 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard practice center</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment center choice.
Excepted: anthracyclines, taxanes, capecitabine and eribulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estramustine</intervention_name>
    <arm_group_label>Estramustine</arm_group_label>
    <other_name>estracyt, estramustine phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard practice</intervention_name>
    <description>standard practice</description>
    <arm_group_label>Standard practice center</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic breast cancer HER2-/RH+

          -  Progression after hormonotherapy

          -  Treated by taxanes, anthracyclines, capecitabine and eribulin

          -  Treated by everolimus

          -  ECOG ≤ 2

          -  Hematological Function: neutrophiles ≥ 1,5 x 109 / L, hemoglobin ≥ 9 g / dL, plaques ≥
             100 x 109 / L

          -  Hepatic function: albumin ≥ 2,5 g / dl, bilirubin serum ≤ 2 x N (superior border of
             the standard) (unless disease of Gilbert), transaminases ≥ 3 x N

          -  Renal Function: serum creatinine ≤ 1,5 mg / dL or clearance of the creatinine ≥ 40 mL
             / min

          -  Estimated Life expectancy ≥ 3 months

        Exclusion Criteria:

          -  Hypersensitivity known about one of the constituents of the estramustine phosphates

          -  Preliminary Treatment by estramustine phosphates

          -  Brain Metastases

          -  Patients not being under effective contraception

          -  Minor, pregnant or lactating Patients

          -  Patients not previously treated by everolimus

          -  Transaminases &gt; 3xN

          -  Other concomitant anticancer treatment less than 1 month before the inclusion

          -  Digestive function: malabsorption

          -  History of other cancer in the previous 5 years (other than squamous-cell epithelioma
             or totally resected in situ carcinoma)

          -  Active Thrombo-phlebitis

          -  Risk thromboembolic known,

          -  Unchecked cardiovascular Pathology

          -  Grave hepatic Affection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cristian VILLANUEVA</last_name>
    <email>c1villanueva@chu-besancon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise ROBERT</last_name>
      <email>e1robert@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Committee shall meet twice a year</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

